|Description||Adipiplon is GABAA receptor partial agonist. It can bind to the α3 subtype. Adipiplon is one of the first drugs selected for clinical development which is able to discriminate between α2 and α3, as well as showing little affinity for the α1 or α5 subtypes .Adipiplon is being researched as a potential medication for the treatment of anxiety and insomnia, and in 2008 it was being used in Phase IIb trials. But these trials were suspended after next-day side effects were discovered.|
|Solubility||Soluble in DMSO|
|Application||anxiety and insomnia|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Ligand Pharmaceuticals|
CGP52432 is a potent and selective GABAB receptor antagonist with IC50 value of 85 nM.
CGP 54626 hydrochloride
The hydrochloride salt form of CGP 54626, a dichloropheny derivative, has been found to be a GABAB receptor antagonist that could probably be effective as an an...
CP-457920, also called as NGD 971, is a selective α5 GABAA receptor inverse agonist (Ki of ~ 1 ng/mL). CP-457920 was progressed into clinical studies for the tr...
Gaboxadol is a GABA agonist. It was a non-opioid analgesic and a novel type of hypnotic. It was first synthesized in 1977 by the Danish chemist Povl Krogsgaard-...
Nefiracetam is a GABAergic, cholinergic, and monoaminergic neuronal system enhancer for Ro 5-4864-induced convulsions.
TPA023, also called as MK-0777, is a subtype-selective, mixed agonist-antagonist at GABAA receptor with anxiolytic and anticonvulsant effects.
Lesogaberan is a potent and selective GABAB receptor agonist that limit the clinical use of baclofen for the treatment of GERD.
CGP7930 is a positive allosteric modulator at the GABAB receptor. It has anxiolytic effects in animal studies, and has a synergistic effect with GABAB agonists ...
Arbaclofen placarbil is a prodrug of R-baclofen. It is a GABA B receptor agonist. Arbaclofen was being developed as a potential treatment for patients with GERD...
CH-50911 is a selective GABA-B antagonist with IC50 value of 1.1 μM. It is developed by Schering-Plough Corporation. CH-50911 is often used in pharmacology rese...
Progabide is a gamma-aminobutyric acid (GABA) antagonist. It has agonistic activity for both the GABAA and GABAB receptors. It has antiepileptic activity and is...
BAR-501, a UDCA derivative, is a selective GPBAR1 agonist devoid of any FXR agonistic activity. BAR-501 effectively transactivates GPBAR1 in HEK293 cells overex...
GS 39783 is an allosteric positive modulator of GABAB receptors, decreases cocaine self-administration, blocks the rewarding properties of nicotine and produces...
Ginkgolide A is an extract from in Ginkgo biloba and a g-aminobutyric acid (GABA) antagonist with a Ki of 14.5 μM.
MK 0343, also known as MRK-409, is a subtype-selective GABAA partial agonist (Ki values are 0.21, 0.22, 0.23 and 0.40 for α3, α1, α5 and α2 respectively). MK-03...
NS 11394 is a drug with selectivity for the α3 and α5 subtypes. It acts as a subtype-selective positive allosteric modulator at GABAA receptors. It is used as a...
Etomidate hydrochloride is a GABAA receptor agonist used for the induction of general anaesthesia.
L-DABA, (L-2,4-Diaminobutyric acid) is a noncompetitive GABA transaminase inhibitor (IC50> 500 μM) with antitumor activity in vivo and in vitro.
Indiplon acts as a high-affinity positive and orally active allosteric modulator of the GABAA receptor (Ki=1.2 nM in rat frontal cortex and Ki=1.7 nM and in cer...
Adipiplon is GABAA receptor partial agonist. It can bind to the α3 subtype. Adipiplon is one of the first drugs selected for clinical development which is able ...